Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2007 | -5.92 Million USD | 20.07% |
| 2006 | -4.23 Million USD | -187.02% |
| 2005 | -2.85 Million USD | 81.21% |
| 2004 | -6.88 Million USD | -176.84% |
| 2003 | -2.51 Million USD | -69.29% |
| 2002 | -1.47 Million USD | 0.0% |
| 1999 | -1.33 Million USD | -80.9% |
| 1998 | -720.12 Thousand USD | -569.87% |
| 1997 | 204.71 Thousand USD | -51.28% |
| 1996 | 450.47 Thousand USD | 284.21% |
| 1995 | 100 Thousand USD | -118.18% |
| 1994 | 1.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2007 Q1 | -1.18 Million USD | 31.91% |
| 2007 FY | - USD | 20.07% |
| 2007 Q4 | -1.05 Million USD | -523.3% |
| 2007 Q3 | -168.88 Thousand USD | -121.41% |
| 2007 Q2 | 788.65 Thousand USD | 166.39% |
| 2006 FY | - USD | -187.02% |
| 2006 Q1 | -651.97 Thousand USD | 5.95% |
| 2006 Q3 | -620.52 Thousand USD | 12.77% |
| 2006 Q4 | -1.74 Million USD | -181.15% |
| 2006 Q2 | -711.34 Thousand USD | -9.11% |
| 2005 Q4 | -693.25 Thousand USD | -69.46% |
| 2005 Q3 | -409.1 Thousand USD | -3752.23% |
| 2005 Q2 | -10.62 Thousand USD | 98.12% |
| 2005 FY | - USD | 81.21% |
| 2005 Q1 | -563.53 Thousand USD | 49.93% |
| 2004 Q1 | -3.99 Million USD | -10597.01% |
| 2004 FY | - USD | -176.84% |
| 2004 Q4 | -1.12 Million USD | -58.74% |
| 2004 Q3 | -709.07 Thousand USD | 34.67% |
| 2004 Q2 | -1.08 Million USD | 72.83% |
| 2003 Q4 | 38.05 Thousand USD | 104.04% |
| 2003 FY | - USD | -69.29% |
| 2003 Q3 | -568.54 Thousand USD | -92.66% |
| 2003 Q1 | -935.44 Thousand USD | 0.0% |
| 2003 Q2 | -145.37 Thousand USD | 15.62% |
| 2002 FY | - USD | 0.0% |
| 2000 Q2 | -514.03 Thousand USD | 16.76% |
| 2000 Q1 | -618.47 Thousand USD | 31.46% |
| 1999 FY | - USD | -80.9% |
| 1999 Q4 | -891.02 Thousand USD | -1212.42% |
| 1999 Q3 | -102.67 Thousand USD | 0.0% |
| 1998 FY | - USD | -569.87% |
| 1997 Q1 | 200 Thousand USD | 180.15% |
| 1997 FY | - USD | -51.28% |
| 1996 Q1 | 400 Thousand USD | 100.0% |
| 1996 Q2 | 400 Thousand USD | 0.0% |
| 1996 FY | - USD | 284.21% |
| 1996 Q3 | -100 Thousand USD | -125.0% |
| 1996 Q4 | -249.52 Thousand USD | -149.52% |
| 1995 Q2 | -100 Thousand USD | -200.0% |
| 1995 Q4 | - USD | 300.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q1 | 100 Thousand USD | -66.67% |
| 1995 FY | - USD | -118.18% |
| 1994 Q2 | 900 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | -77.78% |
| 1994 Q4 | 300 Thousand USD | 50.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | 900 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 91.654% |
| SQZ Biotechnologies Company | -64.14 Million USD | 90.756% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 65.867% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 106.305% |
| Mesoblast Limited | -62.38 Million USD | 90.497% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -285.984% |
| Genus plc | 73.7 Million USD | 108.045% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 10.325% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -67.153% |
| Marizyme, Inc. | -34.28 Million USD | 82.705% |
| ContraFect Corporation | -64.99 Million USD | 90.878% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 32.411% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -30.991% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -322.947% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -124.202% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -155.136% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1044.475% |
| Accustem Sciences Inc. | -3.74 Million USD | -58.255% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 87.706% |
| EV Biologics, Inc. | -1.26 Million USD | -367.9% |
| Q BioMed Inc. | -617.62 Thousand USD | -859.948% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 265.983% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -837.516% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -159.529% |
| Biomind Labs Inc. | -1.03 Million USD | -473.091% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 160.027% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 17.209% |
| Skye Bioscience, Inc. | -13.54 Million USD | 56.236% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -298.606% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -23615.636% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -52.637% |
| IMV Inc. | -35.52 Million USD | 83.31% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 62.64% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -136.97% |
| GB Sciences, Inc. | -1.41 Million USD | -317.563% |
| Alpha Cognition Inc. | -9.7 Million USD | 38.913% |
| HST Global, Inc. | -5303.00 USD | -111702.923% |
| CSL Limited | 4.78 Billion USD | 100.124% |
| Halberd Corporation | -74.27 Thousand USD | -7881.945% |
| Enzolytics Inc. | -2.12 Million USD | -179.398% |
| Resverlogix Corp. | -11.74 Million USD | 49.507% |
| Affymax, Inc. | -14.29 Million USD | 58.525% |
| SYBLEU INC | -141.57 Thousand USD | -4087.94% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -93.564% |
| argenx SE | -216.02 Million USD | 97.255% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 89.286% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 587.174% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -295.549% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1665.0% |
| AVAX Technologies, Inc. | -6.11 Million USD | 3.006% |
| Zenith Capital Corp. | -8.6 Million USD | 31.107% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.616% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -33933.115% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -142.346% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -3268.232% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 85.042% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -104.988% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -466.648% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 88275.327% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -238.795% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -208.651% |
| BioStem Technologies, Inc. | -7.55 Million USD | 21.509% |
| ONE Bio Corp. | 13.61 Million USD | 143.553% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -3174.049% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -188.231% |
| Agentix Corp. | -1.37 Million USD | -332.213% |
| LadRx Corporation | 412.28 Thousand USD | 1538.068% |
| Cell Source, Inc. | -4.27 Million USD | -38.768% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1514.534% |
| Regen BioPharma, Inc. | 1.46 Million USD | 504.44% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -532.789% |
| NovAccess Global Inc. | -1.03 Million USD | -472.954% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 166.965% |
| Itoco Inc. | -1.86 Million USD | -217.224% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1461.801% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -431.264% |
| Kadimastem Ltd | -2.62 Million USD | -125.916% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2379.159% |
| CytoDyn Inc. | -18.02 Million USD | 67.115% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -7402.194% |
| Mobile Lads Corp. | -2.24 Million USD | -164.547% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -48382.37% |
| Qrons Inc. | -40.08 Thousand USD | -14692.318% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1120.749% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1224.107% |
| Rebus Holdings, Inc. | -951 Thousand USD | -523.439% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -458.272% |
| International Stem Cell Corporation | 202 Thousand USD | 3035.103% |
| Bioxytran, Inc. | -3.82 Million USD | -55.201% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -11163.125% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -140.823% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 83.471% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -13075.353% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -116.542% |
| Neutra Corp. | -181.24 Thousand USD | -3171.176% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 70.589% |
| PureTech Health plc | -11.62 Million USD | 49.007% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 70.587% |
| IXICO plc | -707 Thousand USD | -738.601% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 22.851% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 87.737% |
| CSL Limited | 4.73 Billion USD | 100.125% |
| Cellectis S.A. | -92.63 Million USD | 93.6% |